OMNICELL, INC. (NASDAQ:OMCL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
(the Committee) of the Board of Directors of Omnicell, Inc. (the
Company), the Committee approved the 2017 annualized base
salaries for the Companys executive officers as set forth below.
The Committee determined not to change the executive officers
annualized base salaries from the salaries then in effect. In
addition, the Committee granted long-term equity compensation
awards to the Companys executive officers in the amounts set
forth below.
|
Long-Term Equity Compensation
|
||||||||||||||
|
Name
|
Title
|
2017 Annualized Base Salary
|
2017 Annual Cash Bonus Target as % of Base Salary
|
Stock Option Grant(1)
|
Restricted Stock Units (time based) (2)
|
Restricted Stock Units (performance based)(3)
|
||||||||
|
Randall A. Lipps
|
Chairman, President and Chief Executive Officer
|
$
|
660,000
|
%
|
134,160
|
16,350
|
54,500
|
|||||||
|
Peter J. Kuipers
|
Executive Vice President and Chief Financial Officer
|
$
|
375,000
|
%
|
30,190
4,200
|
(4)
|
3,680
|
(4)
|
12,260
1,700
|
(4)
|
||||
|
J. Christopher Drew
|
President, North American Automation
|
$
|
375,000
|
%
|
30,190 5,030
|
(4)
|
3,680
|
(4)
|
12,260
2,050
|
(4)
|
||||
|
Robin G. Seim
|
President, Global Automation and Medication Adherence
|
$
|
375,000
|
%
|
30,190 4,200
|
(4)
|
3,680
|
(4)
|
12,260
1,700
|
(4)
|
||||
|
Nhat Ngo
|
Executive Vice President, Strategy and Business
Development |
$
|
300,000
|
%
|
21,800 1,680
|
(4)
|
2,660
|
(4)
|
8,860
|
(4)
|
||||
|
Dan S. Johnston
|
Executive Vice President and Chief Legal and
Administrative Officer |
$
|
300,000
|
%
|
21,800
1,680
|
(4)
|
2,660
|
(4)
|
8,860
|
(4)
|
||||
|
Jorge Taborga
|
Executive Vice President, Engineering
|
$
|
285,000
|
%
|
21,800 3,350
|
(4)
|
2,660
|
(4)
|
8,860
1,360
|
(4)
|
||||
equal to the closing price of the Companys stock on the date of
grant, February 8, 2017, as reported on The NASDAQ Global Market,
which was $36.70 per share. The shares subject to each of the
stock option grants vest as follows: 25% of the shares subject to
the grant shall vest on the first anniversary of the vesting
commencement date of such grants, February 8, 2018, with the
remainder of the shares subject to the grant vesting in equal
monthly installments over the following thirty-six months.
semi-annual basis over a period of four years commencing on June
15, 2017.
follows: 25% of the shares subject to the performance-based
restricted stock unit awards shall vest, if at all, on the date
of the Committee meeting in 2018 when the Committee reviews the
Company stock performance objectives as compared to the NASDAQ
Healthcare Index and certifies in writing the extent to which the
objectives were met, with the remaining 75% of the shares subject
to the performance-based restricted stock unit award vesting on a
semi-annual basis over a period of thirty-six months commencing
on June 15, 2018 only if and to the extent the Committee
certifies in writing that the stock performance objectives were
met. The actual number of shares that vest subject to the
performance-based restricted stock units may be 0%, 50% or 50% of
the numbers reflected above, depending upon the Companys
performance.
Mr. Lipps) for their outstanding performance during 2016.
|
Exhibit Number
|
Description
|
|
|
10.1
|
2017 Executive Officer Annual Base Salaries
|
About OMNICELL, INC. (NASDAQ:OMCL)
Omnicell, Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment organizes the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. Its product line includes OmniRx, SinglePointe, AnywhereRN, Omnicell and Pandora Data Analytics, Savvy Mobile Medication System, Central Pharmacy and Satellite Pharmacy Manager, Anesthesia Workstation and Advanced Interoperability products. OMNICELL, INC. (NASDAQ:OMCL) Recent Trading Information
OMNICELL, INC. (NASDAQ:OMCL) closed its last trading session down -0.10 at 37.30 with 208,353 shares trading hands.
